177Lu-PSMA-617放射性配体治疗转移性去势抵抗性前列腺癌:REALITY研究254例前瞻性登记结果
REALITY研究前瞻性登记分析了254例日常临床实践中的转移性去势抵抗性前列腺癌(mCRPC)患者,接受177Lu-PSMA-617放射性配体治疗。结果显示52.0%患者PSA下降≥50%,PSA无进展生存期5.5个月,总生存期14.5个月;治疗安全可耐受,早期生化应答与更好总生存相关。
要点
- 177Lu-PSMA-617治疗mCRPC的PSA应答率52.0%,中位OS 14.5个月
- 初始≤2次治疗应答是OS最强预后因素(HR 3.7)
- 3/4级不良事件以贫血7.1%、血小板减少4.3%为主,无治疗相关死亡
核心结论
- 在晚期/终末期mCRPC且常规治疗失败的真实世界队列中,177Lu-PSMA-617放射性配体治疗有效、安全且耐受良好。
- 早期生化疾病控制与更好的总生存相关。
- 可能有必要在疾病早期阶段进行前瞻性研究。
研究设计与样本
- 前瞻性收集的登记数据,分析254例连续mCRPC男性患者,均接受177Lu-PSMA-617放射性配体治疗。
- 患者中位年龄70岁,74.0%(188/254)既往接受过紫杉烷类治疗,32.7%(83/254)有内脏转移。
- 主要终点为PSA应答、PSA无进展生存期(PSA-PFS)和总生存期(OS),采用Kaplan-Meier统计。
主要发现
- 患者接受3(1-13)次177Lu-PSMA-617治疗,每周期6.5(2.5-11.6)GBq,每5.7(3.0-11.0)周一次。
- 最佳应答为52.0%(132/254)患者PSA下降≥50%。
- PSA-PFS为5.5个月(95%CI 4.4-6.6),OS为14.5个月(95%CI 11.5-17.5)。
- 多变量Cox模型显示,初始≤2次治疗应答是与OS相关的最强显著预后因素(HR 3.7,95%CI 2.5-5.5,p<0.001)。
- 无治疗相关死亡或治疗中止;最常见3/4级不良事件为贫血(7.1%)、血小板减少(4.3%)、淋巴细胞减少(2.8%);1/2级口干20.9%。
临床怎么用
- 对于常规治疗失败的晚期mCRPC患者,177Lu-PSMA-617可作为有效且安全的 salvage 治疗选择。
- 治疗早期(≤2次)PSA应答可辅助判断预后,指导后续治疗决策。
局限性
- 为前瞻性登记的真实世界研究,非随机对照试验。
- 患者群体为老年、经重度治疗且疾病晚期,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Preliminary data from retrospective analyses and recent data from large randomized controlled trials suggest safety and efficacy of radioligand therapy (RLT) targeting prostate-specific membrane antigen (PSMA) in men with metastatic castration-resistant prostate cancer (mCRPC). Limited data on this modality have been published regarding large samples treated in everyday practice. METHODS: We analyzed prospectively collected registry data regarding lutetium-177 (177Lu)-PSMA-617 RLT of 254 consecutive men with mCRPC seen in everyday academic practice. Since 177Lu-PSMA-617 was experimental salvage treatment following failure of individually appropriate conventional therapies, patients were generally elderly and heavily pretreated (median age 70 years; prior taxanes 74.0%, 188/254), with late-end-stage disease (visceral metastasis in 32.7%, 83/254). Primary endpoints were response to RLT, defined by changes from baseline serum prostate-specific antigen (PSA) concentration, PSA progression-free survival (PSA-PFS), and overall survival (OS), estimated with Kaplan-Meier statistics, and caregiver-reported and patient-reported safety. Unless noted, median (minimum-maximum) values are given. RESULTS: Patients received 3 (1-13) 177Lu-PSMA-617 activities (6.5 [2.5-11.6] GBq/cycle) every 5.7 (3.0-11.0) weeks. Best response was ≥ 50% PSA reduction in 52.0% of patients (132/254). PSA-PFS was 5.5 (95% confidence interval [95%CI] 4.4-6.6) months and OS, 14.5 (95%CI 11.5-17.5) months. In multivariable Cox proportional-hazards modeling, response to the initial ≤ 2 RLT administrations was the strongest significant prognosticator related to OS (hazard ratio 3.7 [95%CI 2.5-5.5], p < 0.001). No RLT-related deaths or treatment discontinuations occurred; the most frequent RLT-related Grade 3/4 adverse events were anemia (18/254 patients, 7.1%), thrombocytopenia (11/254, 4.3%), and lymphopenia (7/254, 2.8%). RLT-related xerostomia, all grade 1/2, was noted in 53/254 (20.9%). CONCLUSIONS: In a large, prospectively observed "real-world" cohort with late-stage/end-stage mCRPC and conventional treatment failure, 177Lu-PSMA-617 RLT was effective, safe, and well-tolerated. Early biochemical disease control by such therapy was associated with better OS. Prospective study earlier in the disease course may be warranted.
引用
- Khreish F, Ghazal Z, Marlowe RJ, et al. 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study). Eur J Nucl Med Mol Imaging. 2021. PMID: 34494131. doi:10.1007/s00259-021-05525-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。